Stay updated with breaking news from Rahuls Dalal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.
At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.
Retrospective study found no increased risk versus anti-TNF agents, but more research is needed